2 Information about erenumab
Marketing authorisation indication
2.1 Erenumab (Aimovig, Novartis) is indicated for 'prophylaxis of migraine in adults who have at least 4 migraine days per month'.
Dosage in the marketing authorisation
2.2 The dosage schedule is available in the summary of product characteristics.
Price
2.3 The list price of erenumab is £386.50 per 70 mg or 140 mg injection (excluding VAT, BNF online, accessed November 2020). The company has a commercial arrangement. This makes erenumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.